# Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer

> **NCT03576963** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **University of Southern California**

## Conditions studied

- Colorectal Adenocarcinoma
- CpG Island Methylator Phenotype
- Metastatic Microsatellite Stable Colorectal Carcinoma
- Refractory Colorectal Carcinoma
- Stage IV Colorectal Cancer AJCC v8
- Stage IVA Colorectal Cancer AJCC v8
- Stage IVB Colorectal Cancer AJCC v8
- Stage IVC Colorectal Cancer AJCC v8

## Interventions

- **DRUG:** Guadecitabine
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT03576963
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-01-30
- **Primary completion:** 2022-01-30
- **Final completion:** 2023-01-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No funding
- **Last updated:** 2021-04-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03576963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03576963, "Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT03576963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*